EGFR and neoplasm: In EGFR-mutant NSCLC, tumor microenvironment (TME) tends to be a poorly immunogenic “immune desert” phenotype (40), and thus, it could be speculated that blocking PD-1/PD-L1 would enhance tumor growth and lead to resistance to ICIs, even HPD.